Page 75 - CIBERDEM-2015-eng

we are developing the project “Retinal Neurode- Alzheimer´s disease” funded by European Founda- generation in Type 2 diabetes as biomarker for tionfortheStudyofDiabetes(EFSD).
Most relevant scientific articles
Research groups
SIMO R., SAEZ-LóPEZ C., BARBOSA-DESONGLES A., HERNáN- DEZ C., SELVA D.M.. Novel insights in SHBG regulation and clinical implications. Trends in Endocrinology and Metab- olism. 2015;26(7):376-383.
SIMO R., HERNáNDEZ C.. Novel approaches for treating di- abetic retinopathy based on recent pathogenic evidence. Progress in Retinal and Eye Research. 2015;48:160-180.
SAEZ-LóPEZ C., RIVERA-GIMéNEZ M., HERNáNDEZ C., SIMO R., SELVA D.M.. SHBG-C57BL/ksJ-db/db: A new mouse model to study SHBG expression and regulation during obesity development. Endocrinology. 2015;156(12):4571-4581.
Highlights
The outstanding advances for research lines are the follows:
Pathophysiology of diabetic retinopathy (DR): We have characterized retinal neurodegeneration in db/ db mice and we have found that this model repro- duces the morphological and functional events that occur in the human diabetic eye. Therefore, the db/ db mouse is very useful to gain new insights into the mechanisms that lead to the neurodegeneration of the retina induced by diabetes and to test neuropro- tective agents for DR (Projects PI13/00603; FP7- 278040; SAF2012-35562). Among the drugs tested, it should be noted the efficacy observed with GLP- 1 administered in eye drops to prevent neurode- generation and early microvascular damage in db/ db mice. We are conducting the preclinical studies required for assessing GLP-1 use in humans (Pro- ject DTS15/00151). Our main objective is to use the knowhow and international leadership of the group in this field to be pioneers in the development of top- ical treatments and new drug formulations for early stages of RD.
Patents generated and managed in 2015 directly re- lated to this topic:
• PCT/ES/2015/070415.
• PCT/EP2014/053787 and PCT/EP2013/058836 (2015: national phase entry).
ZAMORA M., PARDO R., VILLENA J.A.. Pharmacological in- duction of mitochondrial biogenesis as a therapeutic strategy for the treatment of type 2 diabetes. Biochemical Pharmacology. 2015;98(1):16-28.
LECUBE A., SAMPOL G., HERNáNDEZ C., ROMERO O., CIUDIN A., SIMO R.. Characterization of sleep breathing pattern in pa- tients with type 2 diabetes: Sweet sleep study. PLoS ONE. 2015;10(3).
Obesity, insulin resistance and comorbidities: No- tably, within the study of new candidates involved in obsesity and potential therapeutic targets, we have shown that SHBG has lipolytic properties, and particularly in the liver (Project PI12/01357; PI15/00823).
Patent: PCT/EP2014/061218 (2015: national phase entry).
Cardiovascular disease in type 2 diabetes: We are defining a new cardiovascular risk score in type 2 diabetic population with special emphasis in the role of microangiopathy (PIE13/00027).
Diabetes as a risk factor for Alzheimer’s disease (AD): We evaluated the usefulness of the study of neurodegeneration of the retina as a predictor of risk of developing AD (EFSD / Lilly-Mental Health and Di- abetes Project Programme). We also investigated the common pathogenic mechanisms between dia- betes and AD (Project PIE14/0061) and how we can to proceed for the early identification of prodromic AD in type 2 diabetic population (MOPEAD-IMI2-Ho- rizon 2020).
Institution: Fundación Hospital Universitario Vall d’Hebron - Institut de Recerca (VHIR)
Contact: Hospital Vall d’Hebron. Passeig Vall d’Hebron, 119-129. 08035 Barcelona · Tel.: 93 489 41 72 E.mail: [email protected] · Website: http://www.vhir.org
CIBERDEM I Annual report 2015 I 75